Helomics
Precision Therapeutics, Helomics Ink Merger Agreement
Through the deal, Precision Therapeutics will acquire the 75 percent stake in Helomics that it does not already own.
Precision Therapeutics to Acquire Remaining Helomics Shares
Helomics' managing executives will remain to manage TumorGenesis, Precision's newly formed subsidiary for cancer diagnostics and therapy.
Helomics Inks Service Agreement for Ariel Precision Medicine Pancreatic Disease Assay
The assay is based on Ariel's Smart-MD bioinformatics platform, which combines patient symptoms and history with next-generation sequencing data.
Skyline Medical to Acquire Up to 25 Percent of Helomics
The companies partnered last month to develop new personalized cancer diagnostics using the Helomics D-Chip bioinformatics platform.
Helomics, MDNA Partner on Diagnostics
As part of the deal, Helomics will promote MDNA's Prostate Core Mitomic Test and its liquid biopsy Prostate Mitomic Test in select US markets.
Nov 29, 2016